Discovery and preclinical characterization of [ 18 F]PI-2620, a next-generation tau PET tracer for the assessment of tau pathology in Alzheimer ’s disease and other tauopathies

ConclusionsTherefore, [18F]PI-2620 was selected for clinical validation.

http://link.springer.com/10.1007/s00259-019-04397-2

Source: European Journal of Nuclear Medicine and Molecular Imaging - July 30, 2019 Category: Nuclear Medicine Source Type: research

More News: Alzheimer's | Brain | Neurology | Nuclear Medicine | Pathology | PET Scan | Progressive Supranuclear Palsy